Bivalirudin as a Systemic Anticoagulant and Flush Solution Additive for Sequential Mitral and Tricuspid Valve Percutaneous Edge-to-Edge Repair in a Patient With Heparin-Induced Thrombocytopenia

J Cardiothorac Vasc Anesth. 2022 Jun;36(6):1709-1714. doi: 10.1053/j.jvca.2021.03.004. Epub 2021 Mar 6.

Abstract

Herein the case of a patient with a prior history of heparin-induced thrombocytopenia who underwent percutaneous mitral valve edge-to-edge repair that was followed by a tricuspid edge-to-edge repair two months later is presented. Recommendations exist for systemic anticoagulant alternatives for percutaneous mitral valve edge-to-edge repair with the MitraClip device (Abbott, Chicago, IL), but minimal guidance and experience are present regarding alternative systemic anticoagulation during the performance of right-sided interventions, including tricuspid edge-to-edge repair (TriClip; Abbott). Notably, there is no clear consensus regarding the use of an alternative anticoagulant in the catheter flush solution for the delivery systems used during these procedures, particularly for right-sided interventions.

Keywords: MitraClip; TriClip; anticoagulation; bivalirudin; heparin-induced thrombocytopenia; percutaneous valve repair.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Cardiac Catheterization / methods
  • Heart Valve Prosthesis Implantation* / methods
  • Hirudins
  • Humans
  • Mitral Valve Insufficiency* / surgery
  • Peptide Fragments
  • Recombinant Proteins
  • Thrombocytopenia* / chemically induced
  • Treatment Outcome
  • Tricuspid Valve / diagnostic imaging
  • Tricuspid Valve / surgery

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • bivalirudin